Inhibition of MyD88 led to significant reductions in key cytokines associated with MDSC expansion including granulocyte-colony stimulating factor (G-CSF), IL-6, IL-1β and TGF-β, leading to fewer MDSCs and reduced cancer burden. The gene discussed is CSF3; the disease is cancer.